
Elahare announced the new Healthcare Common Procedure Coding System (HCPCS) C-code for ElahereTM (mirvetuximab soravtansine-gynx), issued by the Centers for Medicare & Medicaid Services (CMS). The code C9146 is effective April 1, 2023 for mirvetuximab soravtansine-gynx injection of 1mg and may be used on claims billed under the hospital Outpatient Prospective Payment System.
For more information visit the Elahare website.
Posted 3/23/2023

By championing and encouraging advanced practice providers and allied health professionals to work at the top of their licenses, Wilmot Cancer Institute offers comprehensive care close to home through its breast care program that vastly improves the patient experience.

On the final day of the 43rd National Oncology Conference, a series of interactive panel discussions explored innovative strategies for remote patient monitoring across the globe, improving quality and safety amidst complex treatments, financial challenges in precision medicine and clinical trials, and more.

Day two of the 43rd National Oncology Conference featured lively panel discussions on operationalizing CAR T-cell therapy and bispecific antibodies, building sustainable supportive care services, expanding access amid rising patient volumes, as well as presentations from the six 2026 ACCC Innovator Award Winners.

Day one of ACCC’s 43rd National Oncology Conference featured a national look at financial advocacy, the Psychosocial Oncology Professionals Symposium, announcement of the President’s Theme from 2026-2027 ACCC President Douglas Flora, MD, LSSBB, FACCC, and recognition of the 2026 ACCC Innovators.
